Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2020-002313-18 | EudraCT Number | ||
| N-20200060 | Other Identifier | North Denmark Region Committee in Health Research Ethics |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Odense University Hospital | OTHER |
| Hvidovre University Hospital | OTHER |
| University Hospital Bispebjerg and Frederiksberg | OTHER |
Not provided
Not provided
Not provided
This study will investigate the effect of peripheral acting opioid antagonist (PAMORA) on the disease course of patients with acute inflammation of the pancreas (acute pancreatitis). The study will be conducted by treating hospitalized patients with acute pancreatitis with a PAMORA (methylnaltrexone).
In this study, the effects of peripheral acting µ-opioid receptor antagonists (PAMORA) on disease development and progression in patients with acute pancreatitis (AP) will be investigated. Patients with AP will be administered Methylnaltrexone (Relistor®) intravenously. This medication is defined as the investigational product. Relistor® is approved and sold on the Danish marked for treatment of opioid-induced constipation. This PAMORA have not previously been investigated in patients with pancreatitis. The dose regimes for this study will be according to label. It has previously been shown, in patients with opioid-induced obstipation and healthy subjects, that opioid antagonism incl. PAMORA treatment increases gut motility, relaxes gastrointestinal sphincters, increases the intestinal water content and improves the immune response, without affecting analgesia. The affinity of PAMORAs to the µ-opioid receptors is much stronger than opioid analgesics. Therefore, they as antagonists have the potential to counteract the harmful effects of opioids on the gut mucosa, bacterial translocation and inflammation despite the high levels of exogenous opioids present in patients with pancreatitis. PAMORAs do not cross the blood-brain barrier and consequently do not interfere with analgesia or other central effects of opioids.
We hypothesize that treatment with the PAMORA methylnaltrexone will antagonize the harmful effects of opioids without reducing analgesia in patients with AP and hence reduce disease severity and improve clinical outcomes. If successful, this sub-study will for the first time document the effects of a targeted pharmacotherapy in AP with the potential benefit of improved patient outcomes.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo treatment | Placebo Comparator | Placebo consisting of Ringer's lactate in matched volume to active drug is added to 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump. |
|
| Methylnaltrexone treatment | Active Comparator | 0.15 mg/kg methylnaltrexone will be dissolved in 1000 mL Ringer's lactate solution and given as a continues infusion over 24 hours using an infusion pump. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Placebo treatment | Drug | Active drug/placebo is given for the first 5 days of admission. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Pancreatitis activity scoring system | Difference in Pancreatitis activity scoring system (PASS) score between the methylnaltrexone group and the placebo group. The PASS-score is a weighted score of presence of organ failure, number of criterias of Systemic Inflammatory Response Syndrome fulfilled, abdominal pain (0-10), morphine equivalent dose (mg) and tolerance to solid food. Minimum value is 0 and higher score is equal to higher disease activity. Documentation for the PASS can be found on the following link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519418/ | 48 hours after randomization |
| Measure | Description | Time Frame |
|---|---|---|
| Pancreatitis activity scoring system | Difference PASS scores between subgroups | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Difference in assessments of circulating proinflammatory marker |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Asbjørn M. Drewes, Professor | Mech-Sense, Department of Medical Gastroenterology, Aalborg Hospital | Study Chair |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Mech-Sense, Department of Medical Gastroenterology, Aalborg University Hospital | Aalborg | Jutland | 9000 | Denmark | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 38916223 | Derived | Knoph CS, Cook ME, Novovic S, Hansen MB, Mortensen MB, Nielsen LBJ, Hogsberg IM, Salomon C, Neergaard CEL, Aajwad AJ, Pandanaboyana S, Sorensen LS, Thorlacius-Ussing O, Frokjaer JB, Olesen SS, Drewes AM. No Effect of Methylnaltrexone on Acute Pancreatitis Severity: A Multicenter Randomized Controlled Trial. Am J Gastroenterol. 2024 Nov 1;119(11):2307-2316. doi: 10.14309/ajg.0000000000002904. Epub 2024 Jun 25. | |
| 34924020 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Feb 10, 2023 | Apr 20, 2023 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Dec 9, 2022 | Apr 20, 2023 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D010195 | Pancreatitis |
| ID | Term |
|---|---|
| D010182 | Pancreatic Diseases |
| D004066 | Digestive System Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Methylnaltrexone treatment | Drug | Active drug/placebo is given for the first 5 days of admission. |
|
C-Reactive Protein (mg/L) |
| 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Difference in assessments of circulating pro- and anti-inflammatory markers | Interleukin-6, Interleukin-8, Interleukin-18, Tumor necrosis factor alpha, Cluster of Differentiation 163 (serum) (all measured in pg/mL) | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Intestinal permeability | Difference in intestinal permeability between subgroups using the oral polyethylene glycol 400/4000 test | From 48 to 72 hours after randomization |
| Intestinal motility | Difference in intestinal motility assessed by means of gut/colon transit using a CT-based radiopaque marker method between subgroups | 5 (+/- 1 day) after randomization |
| Pancreatic complications | Difference in pancreatic complications (e.g. edema, fluid collections and necrosis) assessed and quantified with contrast-enhanced CT | Day 5 (+/- 1 day) after randomization |
| Pain intensity | Difference between subgroups in pain intensity measured with the questionaire "modified Brief Pain Inventory short form" on visual analogue scale from 0-10 (0 is no pain and 10 is worst pain). | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Gut function (BSFS) | Difference between subgroups in gut function assessed by The Bristol Stool Form Scale for assessment of stool frequency as well as stool consistency (scale from 1-7, where 1 is firmeste and 7 is softest) | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Gut function (GSRS) | Difference between subgroups in gut function assessed by Gastrointestinal Symptom Rating Scale which is a disease-specific instrument of 15 items combined into five symptom clusters depicting reflux, abdominal pain, indigestion, diarrhea and constipation. The GSRS has a seven-point graded Likert-type scale, where 1 represents absence of troublesome symptoms and 7 represents very troublesome symptoms. | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Quantification of analgesics | Difference between subgroups in given dose of analgesics (separated into opioids and non-opioids) based on name, administration route and dose | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Use of nutritional support | Difference between subgroups in the use of nutritional support with registration of the used of either oral nutrition, enteral or parenteral nutrition. | 24 hours after randomization and every 24 hours untill end of study at day 5 (after 120 hours) and again at the day 14 follow-up visit |
| Days of hospitalization | Difference between subgroups in days of hospitalization and days on intensive ward | Observation period starts from day of randomization and ends after 12 months or on the day of discharge which ever comes first |
| Use of invasive treatment | Difference between subgroups in use of invasive treatment (e.g. use of drain or surgery) measured in type and frequency of use | Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first |
| Mortality | Difference between subgroups in mortality rate | Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first |
| Health resource utilization | Difference in health resource utilization (measured in frequency and type of health services used (e.g. blood sample, MRI etc.) that can be converted into danish currency for economic analyses) between subgroups based on service codes (all services have unique service codes stored digitally). | Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first |
| Disease severity | Disease severity classified by the revised Atlanta classification system in 3 levels; Mild, Moderate or Severe acute pancreatitis. (Mild acute pancreatitis, with no organ failure, local or systemic complications, Moderately severe acute pancreatitis is with presence of transient organ failure, local complications or exacerbation of co-morbid disease. Severe acute pancreatitis with persistent organ failure (>48 h). | Observation period starts from day of randomization and ends after 12 months or on the day of discharge whichever comes first |
| Digestive Disease Center K, Bispebjerg University Hospital |
| Bispebjerg |
| Denmark |
| Gastrounit, Hvidovre University Hospital | Hvidovre | Denmark |
| Odense Pancreas Center | Svendborg | Denmark |
| Derived |
| Knoph CS, Cook ME, Fjelsted CA, Novovic S, Mortensen MB, Nielsen LBJ, Hansen MB, Frokjaer JB, Olesen SS, Drewes AM. Effects of the peripherally acting mu-opioid receptor antagonist methylnaltrexone on acute pancreatitis severity: study protocol for a multicentre double-blind randomised placebo-controlled interventional trial, the PAMORA-AP trial. Trials. 2021 Dec 19;22(1):940. doi: 10.1186/s13063-021-05885-3. |